Phelps Brand Welcomes World Champion Swimmer Penny Oleksiak as Global Brand Ambassador
8.10.2020 18:00:00 EEST | Business Wire | Press release
Phelps Brand today announced Canada’s youngest World Champion swimmer Penny Oleksiak is joining the team as an official global ambassador. As part of the Phelps Team, Oleksiak will train and compete utilizing the industry-leading range of products from training equipment to performance swim suits, including the FINA-approved Matrix Technical suit, which is available now to consumers worldwide at www.michaelphelps.com.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201008005297/en/
Michael Phelps welcomes World Champion swimmer Penny Oleksiak to the Phelps Brand. Photo courtesy of Phelps Brand.
Oleksiak, a World Champion swimmer and Olympic-record holder, has been tapped as the face of the Matrix campaign, the Phelps Brand’s first new product launch in 2020. As part of the Phelps Team, Oleksiak (CAN) will help advance the brand globally alongside the growing roster of elite athletes including World Champion and American-record holder Chase Kalisz (USA), two-time Olympian Georgia Davies (UK), French-record holder David Aubry (FRA) and Olympian Luca Pizzini (IT).
“I’m a big fan of Penny and what she’s been able to accomplish in the pool. I’m thrilled she is joining the Phelps Team as the first female global ambassador,” said Phelps. “Penny is a tremendous athlete who shares my passion for the sport and has already provided a lot of great insights for the Phelps Brand. Her personality, talent and confidence are huge assets for the entire swimming community.”
A four-time Olympic medalist and six-time World Championship medalist, Oleksiak is a force on Team Canada. As Canada’s youngest Olympic gold medalist, she holds the nation’s record for most Olympic medals at a single summer games. In her short career she has become known for her exciting come from behind victories, winning four Olympic and six World medals; and currently holds the Olympic Record for the 100 Freestyle.
“I am so excited to be part of the Phelps Team,” said Oleksiak. “I have looked up to Michael my entire career and now have the chance to learn from and work alongside him to bring an incredible experience and line of products to the swimming community. It really is a dream come true for me.”
The Phelps Brand, which originally launched as MP Brand in 2015, continues to develop technologically advanced racing and training suits for competitive swimmers under the direction of Michael Phelps and Hall of Fame coach Bob Bowman.
The first product to launch under the Phelps Brand is the Matrix Tech Suit, a top-of-the-line FINA-approved competitive tech suit created with propriety Exo-Core technology. The Matrix features both adaptive compression material to reduce muscle vibration and drag while ensuring maximum flexibility and freedom of movement. In addition, the Matrix includes a sustaining tape system for improved body position by utilizing front and back axis tape and cross-coordinating to improve length and position.
“Penny is a tremendous athlete and her unique experiences and insights will play a key role in helping inform the competitive swim product innovation in the Phelps Brand today,” said Andrew Gritzbaugh, General Manager of North America for Aqua Lung, the parent company of Phelps Brand and Aqua Sphere. “We’re very excited to welcome her to the team and look forward to supporting her in her future endeavors.”
To purchase Phelps Brand products go to www.michaelphelps.com.
About PHELPS BRAND
The Phelps Brand offers best-in-class, innovative swim products that are inclusive and accessible to a broad range of swimmers across the competitive swimming lifecycle. Combining Aqua Sphere’s global product design expertise and distribution with Michael Phelps’ and Coach Bob Bowman’s experiences at the highest levels of swim performance, the Phelps Brand features technical swim products leveraging proprietary technologies and performance enhancing designs. For more information, visit www.michaelphelps.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201008005297/en/
Contact information
Lindsay Goodson
lgoodson@aqualung.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom